|
1
|
Ueno M, Kiba T, Nishimura T, Kitano T,
Yanagihara K, Yoshikawa K, Ishiguro H, Teramukai S, Fukushima M,
Kato H and Inamoto T: Changes in survival during the past two
decades for breast cancer at the Kyoto university hospital. Eur J
Surg Oncol. 33:696–699. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Petrelli F, Cabiddu M, Cazzaniga ME,
Cremonesi M and Barni S: Targeted therapies for the treatment of
breast cancer in the posttrastuzumab era. Oncologist. 13:373–381.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Beslija S, Bonneterre J, Burstein H,
Cocquyt V, Gnant M, Goodwin P, Heinemann V, Jassem J, Köstler WJ,
Krainer M, et al: Second consensus on medical treatment of
metastatic breast cancer. Ann Oncol. 18:215–225. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ueno NT, Buzdar AU, Singletary SE, Ames
FC, McNeese MD, Holmes FA, Theriault RL, Strom EA, Wasaff BJ, Asmar
L, et al: Combined-modality treatment of inflammatory breast
carcinoma: Twenty years of experience at M. D. Anderson cancer
center. Cancer Chemother Pharmacol. 40:321–329. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Révillion F, Bonneterre J and Peyrat JP:
ERBB2 oncogene in human breast cancer and its clinical
significance. Eur J Cancer. 34:791–808. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Muñoz-Couselo E, Pérez-García J and Cortés
J: Eribulin mesylate as a microtubule inhibitor for treatment of
patients with metastatic breast cancer. Onco Targets Ther.
4:185–192. 2011.PubMed/NCBI
|
|
7
|
Jimeno A: Eribulin: Rediscovering tubulin
as an anticancer target. Clin Cancer Res. 15:3903–3905. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Smith JA, Wilson L, Azarenko O, Zhu X,
Lewis BM, Littlefield BA and Jordan MA: Eribulin binds at
microtubule ends to a single site on tubulin to suppress dynamic
instability. Biochemistry. 49:1331–1337. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huyck TK, Gradishar W, Manuguid F and
Kirkpatrick P: Eribulin mesylate. Nat Rev Drug Discov. 10:173–174.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hamel E: Natural products which interact
with tubulin in the vinca domain: Maytansine, rhizoxin, phomopsin
A, dolastatins 10 and 15 and halichondrin B. Pharmacol Ther.
55:31–51. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Towle MJ, Salvato KA, Budrow J, Wels BF,
Kuznetsov G, Aalfs KK, Welsh S, Zheng W, Seletsky BM, Palme MH, et
al: In vitro and in vivo anticancer activities of synthetic
macrocyclic ketone analogues of halichondrin B. Cancer Res.
61:1013–1021. 2001.PubMed/NCBI
|
|
12
|
Newman S: Eribulin, a simplified ketone
analog of the tubulin inhibitor halichondrin B, for the potential
treatment of cancer. Curr Opin Investig Drugs. 8:1057–1066.
2007.PubMed/NCBI
|
|
13
|
Cortes J, O'Shaughnessy J, Loesch D, Blum
JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V,
Delozier T, et al: Eribulin monotherapy versus treatment of
physician's choice in patients with metastatic breast cancer
(EMBRACE): A phase 3 open-label randomized study. Lancet.
377:914–923. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
García-Martínez E, Gil GL, Benito AC,
González-Billalabeitia E, Conesa MA, García García T, García-Garre
E, Vicente V and de la Peña Ayala F: Tumor-infiltrating immune cell
profiles and their change after neoadjuvant chemotherapy predict
response and prognosis of breast cancer. Breast Cancer Res.
16:4882014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ishida T, Kiba T, Takeda M, Matsuyama K,
Teramukai S, Ishiwata R, Masuda N, Takatsuka Y, Noguchi S, Ishioka
C, et al: Phase II study of capecitabine and trastuzumab
combination chemotherapy in patients with HER2 overexpressing
metastatic breast cancers resistant to both anthracyclines and
taxanes. Cancer Chemother Pharmacol. 64:361–369. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kiba T, Morii N, Takahashi H, Ozaki S,
Atsumi M, Masumoto F and Yamashiro H: Pathological response rate in
hormone-positive breast cancer patients treated with neoadjuvant
FEC and triweekly docetaxel: A case series. Breast Cancer (Dove Med
Press). 7:245–250. 2015.PubMed/NCBI
|
|
17
|
McIntyre K, O'Shaughnessy J, Schwartzberg
L, Glück S, Berrak E, Song JX, Cox D and Vahdat LT: Phase 2 study
of eribulin mesylate as first-line therapy for locally recurrent or
metastatic human epidermal growth factor receptor 2-negative breast
cancer. Breast Cancer Res Treat. 146:321–328. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Smith TJ, Khatcheressian J, Lyman GH, Ozer
H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J,
Cross SJ, et al: 2006 update of recommendations for the use of
white blood cell growth factors: An evidence-based clinical
practice guideline. J Clin Oncol. 24:3187–3205. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. European
organization for research and treatment of cancer, national cancer
institute of the united states, national cancer institute of
Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wilks S, Puhalla S, O'Shaughnessy J,
Schwartzberg L, Berrak E, Song J, Cox D and Vahdat L: Phase 2,
multicenter, single-arm study of eribulin mesylate with trastuzumab
as first-Line therapy for locally recurrent or metastatic
HER2-positive breast cancer. Clin Breast Cancer. 14:405–412. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee JJ and Swain SM: Peripheral neuropathy
induced by microtubule-stabilizing agents. J Clin Oncol.
24:1633–1642. 2006. View Article : Google Scholar : PubMed/NCBI
|
